Masonic Cancer Center

Running trials

• Recruiting

  Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers

  NCT07910019· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  NCT07012044· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

  NCT07265674· Phase 3· J-Pharma Co., Ltd.· Source

• Recruiting

  A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

  NCT06844383· Phase 2· Prostate Cancer Clinical Trials Consortium· Source

• Recruiting

  MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

  NCT07493538· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  NCT07216105· Phase 1· Fate Therapeutics· Source

• Active, not recruiting

  LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer

  NCT07153016· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

  NCT06792825· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  UNTOLD Ovarian Cancer Unmet Needs Survey

  NCT07070726· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  NCT06915025· Phase 3· Imunon· Source

• Recruiting

  Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

  NCT07008638· Phase 1/2· Masonic Cancer Center, University of Minnesota· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

  NCT06894979· Phase 1· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  NCT06536049· Phase 1/2· Yazeed Sawalha· Source

• Recruiting

  Trial of Cell Based Therapy for DMD

  NCT06692426· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise

  NCT05025774· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

  NCT06247787· Phase 1· Children's Oncology Group· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  Adenovirus (RGDCRAdCOX2F)

  NCT06693986· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

  NCT05647265· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Allo HSCT for High Risk Hemoglobinopathies

  NCT06872333· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

  NCT06594445· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  NCT06369285· Phase 2· Puma Biotechnology, Inc.· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  NCT06342986· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Active, not recruiting

  Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

  NCT06097832· Phase 1/2· Nexcella Inc.· Source

• Recruiting

  MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

  NCT06412497· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Active, not recruiting

  A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

  NCT05973487· Phase 1· TScan Therapeutics, Inc.· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

  NCT05863195· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  NCT05761171· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

  NCT05702645· Children's Oncology Group· Source

• Active, not recruiting

  Assessing the Time Demands of Cancer

  NCT05708703· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

  NCT06411795· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Active, not recruiting

  Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

  NCT05146739· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

  NCT05665543· Masonic Cancer Center, University of Minnesota· Source

• Active, not recruiting

  A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

  NCT05812027· TScan Therapeutics, Inc.· Source

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Recruiting

  MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

  NCT05735717· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Allo HSCT Using RIC and PTCy for Hematological Diseases

  NCT05805605· Phase 2· Masonic Cancer Center, University of Minnesota· Source

Showing 50 of 144.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers32 recruiting
• Acute myeloid leukaemia12 recruiting
• Acute lymphoblastic leukaemia11 recruiting
• Ovarian cancer9 recruiting
• Myelodysplastic syndromes8 recruiting
• Colorectal cancer6 recruiting
• Follicular lymphoma5 recruiting
• Lung cancer5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Kidney cancer4 recruiting
• Neuroblastoma4 recruiting
• Chronic myeloid leukaemia3 recruiting
• Down syndrome3 recruiting
• Endometrial cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Pancreatic cancer3 recruiting
• Sarcoma3 recruiting
• Aplastic anaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Mantle cell lymphoma2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Prostate cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• COPD1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Neuroendocrine tumours1 recruiting
• Sickle cell disease1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

  NCT06870539· Mayo Clinic· Source

• Withdrawn

  Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

  NCT05114837· Phase 1/2· Masonic Cancer Center, University of Minnesota· Source

• Withdrawn

  Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

  NCT05700630· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Completed

  App-Assisted Day Reconstruction to Reduce Treatment Burden and Logistic Toxicity in Cancer Patients - Aim 3

  NCT06322992· Daynamica, Inc.· Source

• Terminated

  Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

  NCT05984199· Phase 1/2· Vor Biopharma· Source

• Terminated

  Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

  NCT05883449· Phase 2· Affimed GmbH· Source

• Terminated

  MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  NCT05708924· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Withdrawn

  CISH Inactivated TILs in the Treatment of NSCLC

  NCT05566223· Phase 1/2· Intima Bioscience, Inc.· Source

• Terminated

  A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

  NCT05451849· Phase 1/2· TCR2 Therapeutics· Source

• Terminated

  Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

  NCT05130866· Phase 2/3· Recursion Pharmaceuticals Inc.· Source

• Terminated

  Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

  NCT05357898· Phase 1/2· SQZ Biotechnologies· Source

• Completed

  PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

  NCT05120570· Phase 1/2· Masonic Cancer Center, University of Minnesota· Source

• Terminated

  Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

  NCT04849910· Phase 1/2· Vor Biopharma· Source

• Completed

  FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

  NCT04714372· Phase 1· Masonic Cancer Center, University of Minnesota· Source

• Completed

  Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

  NCT04488354· Phase 1· Calibr, a division of Scripps Research· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

  NCT04450069· Phase 1· Calibr, a division of Scripps Research· Source

• Completed

  Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

  NCT04260698· Phase 3· Gamida Cell ltd· Source

• Completed

  A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

  NCT04426669· Phase 1/2· Intima Bioscience, Inc.· Source

• Completed

  CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

  NCT03934840· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Completed

  A Study of FMT in Patients With AML Allo HSCT in Recipients

  NCT03678493· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Completed

  Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

  NCT03981705· Masonic Cancer Center, University of Minnesota· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT03813147· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

  NCT03710876· Phase 3· Ferring Ventures Limited· Source

• Terminated

  A Phase 1 Study of [225Ac]-FPI-1434 Injection

  NCT03746431· Phase 1· Fusion Pharmaceuticals Inc.· Source

• Completed

  Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

  NCT03554083· Phase 2· Mayo Clinic· Source

• Completed

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

  NCT03320330· Phase 1/2· Children's Oncology Group· Source

• Completed

  Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

  NCT03323034· Phase 1· Children's Oncology Group· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Children's Oncology Group· Source

• Completed

  Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  NCT03223753· Phase 3· Children's Oncology Group· Source

• Completed

  Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

  NCT03300557· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

  NCT02975882· Phase 1· Children's Oncology Group· Source

• Completed

  UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

  NCT02722668· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

  NCT02988466· Phase 2· Masonic Cancer Center, University of Minnesota· Source

• Completed

  Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

  NCT02730299· Phase 3· Gamida Cell ltd· Source

• Terminated

  Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

  NCT01962636· Masonic Cancer Center, University of Minnesota· Source

• Completed

  Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507· Phase 2· Children's Oncology Group· Source

• Completed

  Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091· Phase 2· Children's Oncology Group· Source

• Completed

  Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

  NCT02323880· Phase 1· Children's Oncology Group· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

  NCT02396134· Phase 2· City of Hope Medical Center· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

Showing 50 of 79.

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer59 works · 8 trials